Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term metastatic breast-cancer. Found 12 abstracts

Lerner MB, D'Souza J, Pazina T, Dailey J, Goldsmith BR, Robinson MK, Johnson AT. Hybrids of a Genetically Engineered Antibody and a Carbon Nanotube Transistor for Detection of Prostate Cancer Biomarkers. Acs Nano. 2012 Jun;6(6):5143-9.   PMCID: PMC3383883
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.
Martin LP, Kozloff MF, Herbst RS, Samuel TA, Kim S, Rosbrook B, Tortorici M, Chen Y, Tarazi J, Olszanski AJ, Rado T, Starr A, Cohen RB. Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. British Journal of Cancer. 2012 Oct;107(8):1268-76.   PMCID: PMC3494424
Miller J, Doss M, McQuillen R, Shaller CC, Tolner B, Yu JQ, Chester K, Robinson MK. Impact of expression system on the function of the C6.5 diabody PET radiotracer. Tumor Biology. 2012 Jun;33(3):617-27.   PMCID: not NIH funded
Wang SZ, Astsaturov IA, Bingham CA, McCarthy KM, von Mehren M, Xu W, Alpaugh RK, Tang Y, Littlefield BA, Hawkins LD, Ishizaka ST, Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment. Cancer Immunology Immunotherapy. 2012 Jan;61(1):49-61.   PMCID: PMC3517883
Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology. 2011 Sep;68(3):703-12.   PMCID: not NIH funded
Wong YN, Ottesen RA, Hughes ME, Niland JC, Theriault R, Edge SB, Blayney D, Weeks JC. Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence?. The oncologist. 2011 Jan;16(5):559-65.   PMCID: PMC3228199
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating Tumor Cells: Evolving Evidence and Future Challenges. The oncologist. 2009 Jan;14(11):1070-82.   PMCID: not NIH funded
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nature Biotechnology. 2005 Sep;23(9):1147-57.
Rogatko A, Babb JS, Tighiouart M, Khuri FR, Hudes G. New paradigm in dose-finding trials: Patient-specific dosing and beyond phase I. Clinical Cancer Research. 2005 Aug;11(15):5342-6.
Swaby RF, Bhalla KN. Importance of rational pre-clinical development - Gemcitabine comes of age. CANCER BIOLOGY & THERAPY. 2005 Aug;4(8):872-3.
Gervasoni JE, Hindenburg AA, Vezeridis MP, Schulze S, Wanebo HJ, Mehta S. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis. Anticancer research. 2004 Sep;24(5A):2617-26.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term metastatic breast-cancer

metastatic breast-cancer chemotherapy combination paclitaxel cell lung-cancer bevacizumab colorectal-cancer apoptosis growth receptors pharmacokinetics paclitaxel axitinib-docetaxel-capecitabine-solid tumours phase-ii trial therapy 1990 lkman j-journal of the national cancer institute-v82-p4 ag-013736 monoclonal-antibody trial lymphoma tyrosine kinase inhibitor daunrubicin refractory prostate-cancer biosensors carbon nanotube biosensor-field effect transistor-cancer diagnostics pancreatic carcinoma cells epithelial-cells activation b-cell lymphoma non-hodgkins-lymphoma efficacy breast cancer resistance tissue growth-factor recognition necrosis Toll-like receptor 4 agonist her2 humanized anti-cd22 antibody gemcitabine doxorubicin growth-factor receptor enzyme fusion cell-death early prediction field-effect transistors tumors Breast cancer resistant irinotecan glycosylation anti-cd20 monoclonal-antibody transgenic mice predict survival Solid tumor functionalization 2008 iorean eg-v26-p2008 Phase I outcomes immunotherapy fragment carcinoma family estramustine escalation 1995 oe ys-journal of medicinal chemistry-v38-p816 ibritumomab tiuxetan radioimmunotherapy randomized-trials Circulating tumor cells Prostate cancer single-chain fv Transgenic mouse protein cell cycle arrest experience metabolism docetaxel HER2 pichia-pastoris fc-gamma-ri prognostic value peripheral-blood Antibody therapy Sunitinib refractory low-grade Oncology oncology-group clinical-significance Antiangiogenesis chronic lymphocytic-leukemia chemosensitivity distribution plasma osteopontin design human liver-microsomes advanced colorectal-carcinoma Chemotherapy Colon cancer clinical-trials toxicity polymerase-chain-reaction Antitumor immunity ceramide generation phase-i progression-free NSCLC antigen prostate-cancer positron-emission-tomography receptor agonists HER2 Diabody-Pichia-E coli-PET imaging
Last updated on Thursday, April 02, 2020